Engineers Gate Manager LP Ngm Biopharmaceuticals Inc Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.31 $6,744 - $14,724	11,240 Added 101.91%	22,269 $19,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $11,580 - $37,167	11,029 New	11,029 $11,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $143,750 - $237,772	-13,587 Reduced 33.45%	27,026 $346,000
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $22,054 - $29,704	-1,597 Reduced 3.78%	40,613 $619,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $220,082 - $280,777	12,751 Added 43.28%	42,210 $748,000
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $598,878 - $778,392	-29,721 Reduced 50.22%	29,459 $619,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $538,048 - $1.07 Million	35,727 Added 152.33%	59,180 $1.17 Million
Q1 2021 May 17, 2021	SELL	$24.99 - $31.93 $256,847 - $328,176	-10,278 Reduced 30.47%	23,453 $682,000
Q4 2020 Feb 16, 2021	SELL	$16.21 - $31.44 $171,193 - $332,037	-10,561 Reduced 23.84%	33,731 $1.02 Million
Q3 2020 Nov 16, 2020	SELL	$15.59 - $19.97 $206,006 - $263,883	-13,214 Reduced 22.98%	44,292 $705,000
Q2 2020 Aug 17, 2020	BUY	$11.97 - $23.47 $159,835 - $313,394	13,353 Added 30.24%	57,506 $1.14 Million
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $441,530 - $861,425	44,153 New	44,153 $544,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.